Astellas Expands Cell Therapy Research with New Japan Site for Universal Cells

New Research Site:
Astellas has unveiled a new research site in Japan for its cell therapy arm, Universal Cells, marking a significant expansion in its regenerative medicine efforts.

Transfer of Roles:
The move involves transferring 12 roles from the US to Japan, indicating a strategic shift in the company's global research operations.

Universal Donor Cell Technology:
Universal Cells, acquired by Astellas in 2018, specializes in Universal Donor Cell (UDC) technology, which genetically modifies human leukocyte antigen (HLA) to reduce immune rejection in cell therapies.

Collaboration with Osaka University:
Astellas and its subsidiaries, including Universal Cells, have partnered with Osaka University to develop pluripotent stem cell-derived cartilage organoid cell therapy for intervertebral disc degenerative disease.

Research Focus:
The collaboration aims to merge cartilage tissue creation protocols, UDC technology, and extensive R&D capabilities in cell therapy to advance regenerative therapies.

Global Impact:
Astellas aims to provide cutting-edge UDC technology to academia and startups globally, contributing to the development of next-generation cell therapies.